What 503A Compounding Pharmacies Currently Cannot Make These widely used clinical peptides are not eligible for 503A compounding under current rules: BPC-157 (Body Protective Compound, used for tendon, ligament, and gut-lining repair) TB-500 / Thymosin Beta-4 fragment (recovery and inflammation modulation) CJC-1295 (GHRH analog, used for growth hormone optimization) Ipamorelin (selective GH secretagogue) MOTS-c (mitochondrial-derived peptide, metabolic and longevity research) Epithalon (Epitalon) (telomere-supporting longevity peptide) Semax (cognitive and neuroprotective peptide) GHK-Cu (copper tripeptide for skin and tissue regeneration) AOD-9604 (modified fragment of growth hormone, studied for fat metabolism) These peptides are widely studied
A trained clinician does this routinely
SPL UNCLASSIFIED SECTION SPL UNCLASSIFIED SECTION Reorder #005554 Questions
Summary of Previously Finalized and Newly Finalized REHQR Program Measure Set for CY 2026 to CY 2031 Program Determinations Table 139 summarizes the previously finalized and newly finalized REHQR Program measure set for the CY 2026 to CY 2031 program determinations, which removes the Hospital Commitment to Health Equity (HCHE), Screening for SDOH, and Screen Positive Rate for SDOH measures as discussed in section XIV.C
We have streamlined DSIP therapy to make it simple and effective
